Published by Global Banking & Finance Review®
Posted on July 24, 2025
1 min readLast updated: January 22, 2026
Add as preferred source on GoogleNovartis partners with Matchpoint Therapeutics in a deal worth up to $1 billion to develop oral drugs for inflammatory diseases, with potential global commercialization rights.
(Reuters) -Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases.
Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals.
The company will lead the research and drug development process, using the funding from Novartis.
If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration.
Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones.
(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila and Shinjini Ganguli)
Novartis will pay up to $1 billion to Matchpoint Therapeutics, which includes an upfront payment and research funding.
Matchpoint will develop oral drugs targeting several inflammatory diseases by blocking the activity of a specific protein.
If Novartis exercises its option, it will have global rights to develop and commercialize all products resulting from the collaboration.
Matchpoint will receive up to $60 million in upfront payment and research funding from Novartis.
The article is reported by Christy Santhosh in Bengaluru, with editing by Sriraj Kalluvila and Shinjini Ganguli.
Explore more articles in the Finance category
